Products for Research Use Only

(-) -DHMEQ

CAT: 0804-HY-14645-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14645-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
(-) -DHMEQ (Dehydroxymethylepoxyquinomicin) is a potent, selective and irreversible NF-κB inhibitor that covalently binds to a cysteine residue. (-) -DHMEQ inhibits nuclear translocation of NF-κB and shows anti-inflammatory and anticancer activity[1][2][3].
CAS Number
287194-40-5
Product Name Alternative
Dehydroxymethylepoxyquinomicin
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
NF-κB
Type
Reference compound
Related Pathways
NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/_-_-DHMEQ.html
Purity
99.81
Solubility
DMSO : 95 mg/mL (ultrasonic)
Smiles
O=C1[C@@H](O2)[C@@H]2[C@@H](O)C(NC(C3=C(O)C=CC=C3)=O)=C1
Molecular Formula
C13H11NO5
Molecular Weight
261.23
Precautions
H302, H315, H319, H335
References & Citations
[1]Quach HT, et al. Eudesmane-Type Sesquiterpene Lactones Inhibit Nuclear Translocation of the Nuclear Factor κB Subunit RelB in Response to a Lymphotoxin β Stimulation. Biol Pharm Bull. 2017;40 (10) :1669-1677.|[2]Yinzhi Lin, et al. Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review.|[3]Mariko Watanabe, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005 Oct 1;106 (7) :2462-71.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RelA/p65; RelB

Related Products

CatalogName
HY-163618DHMQ